Olfactory identification deficits occur in patients with Alzheimer's disease (AD), are associated with disease severity, predict conversion from mild cognitive impairment (MCI) to AD and are associated with healthy elderly subjects developing MCI. Odor (olfactory) identification deficits may reflect degeneration of cholinergic inputs to the olfactory bulb and other olfactory brain regions. Acetylcholinesterase inhibitors (ACheI) like donepezil show modest effects in improving cognition but can be associated with adverse effects and increased burden and costs because of the need for prolonged, often lifelong, treatment. Converging findings on odor identification test performance (UPSIT, scratch and sniff 40-item test) from four pilot studies, including two of our own, suggest that acute change in the UPSIT in response to an anticholinergic challenge (atropine nasal spray), incremental change over 8 weeks, and even the baseline UPSIT score by itself, may predict cognitive improvement with ACheI treatment in MCI and AD. If change in odor identification deficits can help to identify which patients should receive ACheI treatment, this simple inexpensive approach will advance the goal of improving personalized treatment, improve selection and monitoring of patients for ACheI treatment, reduce needless ACheI exposure with risk of side effects, and decrease health care costs. Project goals are to evaluate change in odor identification deficits as predictors of improvement in 100 patients with MCI (Study 1) and in 100 patients with mild to moderate AD (Study 2) during open treatment with the ACheI, donepezil. In both studies, we hypothesize that the decrease in UPSIT scores from pre- to post-atropine nasal spray challenge conducted at baseline will be associated with cognitive and global improvement from baseline to both 26 weeks and 52 weeks of donepezil treatment. The rationale is that those MCI patients who have AD brain pathology will have a cholinergic deficit and worsening of odor identification with the acute atropine challenge, and these patients will be more likely to improve with ACheI treatment. In both studies, we hypothesize that the increase in UPSIT scores from baseline (pre-atropine) to 8 weeks of donepezil treatment will be associated with cognitive and global improvement from 0 weeks to both 26 weeks and 52 weeks of donepezil treatment. This is the first systematic effort to evaluate the clinical utility of short-term changes in odor identificatin deficits to predict long-term cognitive and global improvement on ACheI treatment, and includes the first use of an anticholinergic challenge that has a sound neurobiological basis.

Public Health Relevance

This project will evaluate odor identification deficits as predictors of improvement in 100 patients with amnestic mild cognitive impairment (MCI, Study 1) and in 100 patients with mild to moderate Alzheimer's disease (AD, Study 2) who receive open label treatment with the acetylcholinesterase inhibitor medication, donepezil.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Project (R01)
Project #
Application #
Study Section
Adult Psychopathology and Disorders of Aging Study Section (APDA)
Program Officer
Ryan, Laurie M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University (N.Y.)
Schools of Medicine
New York
United States
Zip Code
Lan, Martin J; Ogden, R Todd; Kumar, Dileep et al. (2017) Utility of Molecular and Structural Brain Imaging to Predict Progression from Mild Cognitive Impairment to Dementia. J Alzheimers Dis 60:939-947
Devanand, Davangere P; Liu, Xinhua; Brown, Patrick J (2017) Impact of Functional Deficits in Instrumental Activities of Daily Living in Mild Cognitive Impairment: A Clinical Algorithm to Predict Progression to Dementia. Alzheimer Dis Assoc Disord 31:55-61
Pelton, Gregory H; Soleimani, Laili; Roose, Steven P et al. (2016) Olfactory Deficits Predict Cognitive Improvement on Donepezil in Patients With Depression and Cognitive Impairment: A Randomized Controlled Pilot Study. Alzheimer Dis Assoc Disord 30:67-9
Devanand, D P (2016) Olfactory Identification Deficits, Cognitive Decline, and Dementia in Older Adults. Am J Geriatr Psychiatry 24:1151-1157
Devanand, D P; Lee, Seonjoo; Manly, Jennifer et al. (2015) Olfactory deficits predict cognitive decline and Alzheimer dementia in an urban community. Neurology 84:182-9
Devanand, Davangere P; Lee, Seonjoo; Manly, Jennifer et al. (2015) Olfactory identification deficits and increased mortality in the community. Ann Neurol 78:401-11
Albers, Mark W; Gilmore, Grover C; Kaye, Jeffrey et al. (2015) At the interface of sensory and motor dysfunctions and Alzheimer's disease. Alzheimers Dement 11:70-98
Sharer, James D; Leon-Sarmiento, Fidias E; Morley, James F et al. (2015) Olfactory dysfunction in Parkinson's disease: Positive effect of cigarette smoking. Mov Disord 30:859-62
Masurkar, Arjun V; Devanand, D P (2014) Olfactory Dysfunction in the Elderly: Basic Circuitry and Alterations with Normal Aging and Alzheimer's Disease. Curr Geriatr Rep 3:91-100
Goldman, Jill S; Quinzii, Catarina; Dunning-Broadbent, Jane et al. (2014) Multiple system atrophy and amyotrophic lateral sclerosis in a family with hexanucleotide repeat expansions in C9orf72. JAMA Neurol 71:771-4

Showing the most recent 10 out of 13 publications